{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:07:14Z","timestamp":1782284834403,"version":"3.54.5"},"reference-count":55,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Offer of compensation to the inhabitants of Casale Monferrato deceased or affected by mesothelioma","award":["HERMES (HEreditary Risk in MESothelioma) Project"],"award-info":[{"award-number":["HERMES (HEreditary Risk in MESothelioma) Project"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cisplatin is widely employed as a first-line chemotherapeutic agent for many solid tumors, including malignant pleural mesothelioma (MPM). However, its clinical use is limited by heavy side effects and acquired resistance, the latter being mainly related to enhanced DNA repair. Many clinical trials using combinations of platinum drugs and PARP-1 inhibitors (PARPis) have been carried out, with the hope that such combinations might lead to improved therapeutic efficacy against tumors. Here, the synthesis and efficacy in reducing MPM cell viability of four cisplatin-based Pt(IV) prodrugs containing the PARPi 3-aminobenzamide (3-ABA) fragment are described. The most promising conjugate is more effective than cisplatin or cisplatin\/3-ABA combination, administered in equimolar doses, in inhibiting PARP-1 activity and inducing apoptosis in BRCA1\/2 wild type MPM cells, grown as monolayer or as multicellular spheroids.<\/jats:p>","DOI":"10.3390\/molecules26164740","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T09:35:32Z","timestamp":1628156132000},"page":"4740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-1955","authenticated-orcid":false,"given":"Elisabetta","family":"Gabano","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pinton","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Balzano","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy"},{"name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boumya","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-9454","authenticated-orcid":false,"given":"Domenico","family":"Osella","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moro","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 del Piemonte Orientale, Largo Donegani 2\/3, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-7508","authenticated-orcid":false,"given":"Mauro","family":"Ravera","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Innovazione Tecnologica, Universit\u00e0 del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"ref_1","first-page":"139","article-title":"Mesothelioma in Italy: The Casale Monferrato model to a national epidemiological surveillance system","volume":"54","author":"Comba","year":"2018","journal-title":"Ann. dell\u2019Istituto Super. Sanit\u00e0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152007779314044","article-title":"Biochemical Mechanisms of Cisplatin Cytotoxicity","volume":"7","author":"Cepeda","year":"2007","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"viii72","DOI":"10.1093\/annonc\/mdr528","article-title":"Update on PARP1 inhibitors in ovarian cancer","volume":"22","author":"Sessa","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4161\/cc.24034","article-title":"Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer","volume":"12","author":"Michels","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yasukawa, M., Fujihara, H., Fujimori, H., Kawaguchi, K., Yamada, H., Nakayama, R., Yamamoto, N., Kishi, Y., Hamada, Y., and Masutani, M. (2016). Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030272"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"28116","DOI":"10.18632\/oncotarget.15922","article-title":"Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia","volume":"8","author":"Oei","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28456","DOI":"10.18632\/oncotarget.25466","article-title":"Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells","volume":"9","author":"Novohradsky","year":"2018","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e10131","DOI":"10.1002\/btm2.10131","article-title":"Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer","volume":"4","author":"Mensah","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/cmdc.202000391","article-title":"Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy","volume":"15","author":"Yusoh","year":"2020","journal-title":"Chemmedchem"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/s41388-020-1191-x","article-title":"Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2018.09.031","article-title":"PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection","volume":"137","author":"McQuade","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1039\/c4dt00911h","article-title":"Pros and cons of bifunctional platinum(IV) antitumor prodrugs: Two are (not always) better than one","volume":"43","author":"Gabano","year":"2014","journal-title":"Dalton Trans."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(IV) anticancer prodrugs\u2014Hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalton Trans."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejic.201601278","article-title":"Platinum(IV) Prodrugs\u2014A Step Closer to Ehrlich\u2019s Vision?","volume":"12","author":"Kenny","year":"2017","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jinorgbio.2018.11.008","article-title":"Multi-action Pt(IV) anticancer agents; do we understand how they work?","volume":"191","author":"Gibson","year":"2019","journal-title":"J. Inorg. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ica.2019.04.025","article-title":"A view on multi-action Pt(IV) antitumor prodrugs","volume":"492","author":"Ravera","year":"2019","journal-title":"Inorg. Chim. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111353","DOI":"10.1016\/j.jinorgbio.2020.111353","article-title":"Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?","volume":"217","author":"Gibson","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"ref_25","first-page":"519","article-title":"An update on PARP inhibitors for the treatment of cancer","volume":"8","author":"Benafif","year":"2015","journal-title":"Oncotargets Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1021\/jm010116l","article-title":"Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis","volume":"44","author":"Costantino","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/157340606775197697","article-title":"Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells","volume":"2","author":"Perez","year":"2006","journal-title":"Med. Chem."},{"key":"ref_29","first-page":"1399","article-title":"The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells","volume":"25","author":"Zheng","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_30","first-page":"527","article-title":"Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13*cells","volume":"137","author":"Zhang","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/cas.12281","article-title":"Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition","volume":"104","author":"Sakogawa","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2017.09.074","article-title":"Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1","volume":"141","author":"Xu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16279","DOI":"10.1021\/acs.inorgchem.9b02839","article-title":"Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors","volume":"58","author":"Xu","year":"2019","journal-title":"Inorg. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1021\/acs.inorgchem.0c00445","article-title":"Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules","volume":"59","author":"Babu","year":"2020","journal-title":"Inorg. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"213991","DOI":"10.1016\/j.ccr.2021.213991","article-title":"Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs","volume":"442","author":"Xu","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xu, Z.F., Tang, W.K., Zhou, Q.Y., Chen, S., Siu, C.K., and Zhu, G.Y. (2021). On the hydrolytic stability of unsymmetric platinum(iv) anticancer prodrugs containing axial halogens. Inorg. Chem. Front., 9.","DOI":"10.1039\/D1QI00208B"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1039\/C5DT04905A","article-title":"Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido\/carboxylato prodrugs","volume":"45","author":"Ravera","year":"2016","journal-title":"Dalton Trans."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jinorgbio.2016.11.024","article-title":"May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs?","volume":"167","author":"Ravera","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jinorgbio.2018.09.019","article-title":"Hybrid inorganic (nonporous silica)\/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug","volume":"189","author":"Ravera","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ica.2012.06.005","article-title":"Metallo-drugs in the treatment of malignant pleural mesothelioma","volume":"393","author":"Zanellato","year":"2012","journal-title":"Inorg. Chim. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2015.05.012","article-title":"Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs","volume":"150","author":"Ravera","year":"2015","journal-title":"J. Inorg. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jinorgbio.2016.03.005","article-title":"The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs","volume":"160","author":"Varbanov","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1039\/C2DT32360E","article-title":"Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes","volume":"42","author":"Ermondi","year":"2013","journal-title":"Dalton Trans."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00775-010-0731-1","article-title":"Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes","volume":"16","author":"Platts","year":"2011","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.jinorgbio.2007.12.029","article-title":"Calculation of lipophilicity for Pt(II) complexes: Experimental comparison of several methods","volume":"102","author":"Tetko","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.ccr.2009.01.028","article-title":"Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA","volume":"253","author":"Arnesano","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/ejic.201300001","article-title":"An Updated View of Cisplatin Transport","volume":"2013","author":"Arnesano","year":"2013","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1039\/C5SC04205D","article-title":"Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action","volume":"7","author":"Raveendran","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shamseddin, M., Obacz, J., Garnett, M.J., Rintoul, R.C., Francies, H.E., and Marciniak, S.J. (2021). Use of preclinical models for malignant pleural mesothelioma. Thorax, thoraxjnl-2020-216602.","DOI":"10.1136\/thoraxjnl-2020-216602"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.clispe.2021.100011","article-title":"Hyperspectral characterization of the MSTO-211H cell spheroid model: A FPA\u2013FTIR imaging approach","volume":"3","author":"Notarstefano","year":"2021","journal-title":"Clin. Spectrosc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay","volume":"341","author":"Molina","year":"2013","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jinorgbio.2006.01.035","article-title":"The RP-HPLC measurement and QSPR analysis of log P-o\/w values of several Pt(II) complexes","volume":"100","author":"Platts","year":"2006","journal-title":"J. Inorg. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00280-010-1314-0","article-title":"In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: Evidence for sequence-dependent effects","volume":"67","author":"Zanellato","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jinorgbio.2003.08.014","article-title":"Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)","volume":"98","author":"Ghezzi","year":"2004","journal-title":"J. Inorg. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2217\/epi-2016-0025","article-title":"KDM6B histone demethylase is an epigenetic regulator of estrogen receptor beta expression in human pleural mesothelioma","volume":"8","author":"Manente","year":"2016","journal-title":"Epigenomics"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/16\/4740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:57Z","timestamp":1760164857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/16\/4740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":55,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["molecules26164740"],"URL":"https:\/\/doi.org\/10.3390\/molecules26164740","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}